Literature DB >> 27318807

Sustained clinical benefit of cardiac resynchronization therapy in non-LBBB patients with prolonged PR-interval: MADIT-CRT long-term follow-up.

Martin Stockburger1,2, Arthur J Moss3, Helmut U Klein3, Wojciech Zareba3, Ilan Goldenberg3, Yitschak Biton3, Scott McNitt3, Valentina Kutyifa4.   

Abstract

OBJECTIVE: In MADIT-CRT, patients with non-LBBB (right bundle branch block or nonspecific ventricular conduction delay) and a prolonged PR-interval derived significant clinical benefit from cardiac resynchronization therapy with defibrillator (CRT-D) compared to an implantable cardioverter defibrillator (ICD)-only. We aimed to study the long-term outcome of non-LBBB patients by baseline PR-interval with CRT-D versus ICD-only.
METHODS: Non-LBBB patients (n = 534) were dichotomized based on baseline PR-interval: normal PR (PR < 230 ms), and markedly prolonged PR (PR ≥ 230 ms). The primary end point was heart failure (HF) or death. Secondary end points were HF only and all-cause death.
RESULTS: In patients with a prolonged PR-interval, CRT-D treatment related to a 67 % significant reduction in the risk of HF/death (HR = 0.33, 95 % CI 0.16-0.69, p = 0.003), 69 % decrease in HF (HR = 0.31, 95 % CI 0.14-0.68, p = 0.003), and 76 % reduction in the risk of death (HR = 0.24, 95 % CI 0.07-0.80, p = 0.020) compared to ICD-only (median follow-up 5.8 years). In normal PR-interval patients, CRT-D therapy was associated with a trend towards increased risk of HF/death (HR = 1.49, 95 % CI 0.98-2.25, p = 0.061), and significantly increased mortality (HR = 2.27, 95 % CI 1.16-4.44, p = 0.014). Significant statistical interaction with the PR-interval was demonstrated for all end points. Results were consistent for QRS 130-150 ms and QRS > 150 ms.
CONCLUSION: In MADIT-CRT, non-LBBB patients with a prolonged PR-interval derive sustained long-term clinical benefit with reductions in heart failure or death from CRT-D implantation, compared to an ICD-only. Our findings support implantation of CRT-D in non-LBBB patients with prolonged PR-interval irrespective of baseline QRS duration.

Entities:  

Keywords:  Cardiac resynchronization therapy; First-degree AV block; Left bundle branch block; MADIT-CRT; Non-left bundle branch block; PR-interval

Mesh:

Year:  2016        PMID: 27318807     DOI: 10.1007/s00392-016-1003-z

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  19 in total

1.  Cardiac-resynchronization therapy for mild-to-moderate heart failure.

Authors:  Anthony S L Tang; George A Wells; Mario Talajic; Malcolm O Arnold; Robert Sheldon; Stuart Connolly; Stefan H Hohnloser; Graham Nichol; David H Birnie; John L Sapp; Raymond Yee; Jeffrey S Healey; Jean L Rouleau
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).

Authors:  Michele Brignole; Angelo Auricchio; Gonzalo Baron-Esquivias; Pierre Bordachar; Giuseppe Boriani; Ole-A Breithardt; John Cleland; Jean-Claude Deharo; Victoria Delgado; Perry M Elliott; Bulent Gorenek; Carsten W Israel; Christophe Leclercq; Cecilia Linde; Lluís Mont; Luigi Padeletti; Richard Sutton; Panos E Vardas; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Paulus Kirchhof; Carina Blomstrom-Lundqvist; Luigi P Badano; Farid Aliyev; Dietmar Bänsch; Helmut Baumgartner; Walid Bsata; Peter Buser; Philippe Charron; Jean-Claude Daubert; Dan Dobreanu; Svein Faerestrand; David Hasdai; Arno W Hoes; Jean-Yves Le Heuzey; Hercules Mavrakis; Theresa McDonagh; Jose Luis Merino; Mostapha M Nawar; Jens Cosedis Nielsen; Burkert Pieske; Lidija Poposka; Frank Ruschitzka; Michal Tendera; Isabelle C Van Gelder; Carol M Wilson
Journal:  Eur Heart J       Date:  2013-06-24       Impact factor: 29.983

3.  Usefulness of physiologic dual-chamber pacing in drug-resistant idiopathic dilated cardiomyopathy.

Authors:  M Hochleitner; H Hörtnagl; C K Ng; H Hörtnagl; F Gschnitzer; W Zechmann
Journal:  Am J Cardiol       Date:  1990-07-15       Impact factor: 2.778

4.  Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol.

Authors:  Arthur J Moss; Mary W Brown; David S Cannom; James P Daubert; Mark Estes; Elyse Foster; Henry M Greenberg; W Jackson Hall; Steven L Higgins; Helmut Klein; Mark Pfeffer; David Wilber; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-10       Impact factor: 1.468

5.  Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study.

Authors:  Michael R Gold; Christophe Thébault; Cecilia Linde; William T Abraham; Bart Gerritse; Stefano Ghio; Martin St John Sutton; Jean-Claude Daubert
Journal:  Circulation       Date:  2012-07-10       Impact factor: 29.690

6.  PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy.

Authors:  Valentina Kutyifa; Martin Stockburger; James P Daubert; Fredrik Holmqvist; Brian Olshansky; Claudio Schuger; Helmut Klein; Ilan Goldenberg; Andrew Brenyo; Scott McNitt; Bela Merkely; Wojciech Zareba; Arthur J Moss
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-06-24

Review 7.  Criteria for intraventricular conduction disturbances and pre-excitation. World Health Organizational/International Society and Federation for Cardiology Task Force Ad Hoc.

Authors:  J L Willems; E O Robles de Medina; R Bernard; P Coumel; C Fisch; D Krikler; N A Mazur; F L Meijler; L Mogensen; P Moret
Journal:  J Am Coll Cardiol       Date:  1985-06       Impact factor: 24.094

8.  Long-term efficacy of physiologic dual-chamber pacing in the treatment of end-stage idiopathic dilated cardiomyopathy.

Authors:  M Hochleitner; H Hörtnagl; H Hörtnagl; L Fridrich; F Gschnitzer
Journal:  Am J Cardiol       Date:  1992-11-15       Impact factor: 2.778

9.  Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block.

Authors:  Susan Cheng; Michelle J Keyes; Martin G Larson; Elizabeth L McCabe; Christopher Newton-Cheh; Daniel Levy; Emelia J Benjamin; Ramachandran S Vasan; Thomas J Wang
Journal:  JAMA       Date:  2009-06-24       Impact factor: 56.272

10.  Cardiac-resynchronization therapy for the prevention of heart-failure events.

Authors:  Arthur J Moss; W Jackson Hall; David S Cannom; Helmut Klein; Mary W Brown; James P Daubert; N A Mark Estes; Elyse Foster; Henry Greenberg; Steven L Higgins; Marc A Pfeffer; Scott D Solomon; David Wilber; Wojciech Zareba
Journal:  N Engl J Med       Date:  2009-09-01       Impact factor: 91.245

View more
  18 in total

1.  ICD lead type and RV lead position in CRT-D recipients.

Authors:  Alexander P Benz; Mate Vamos; Julia W Erath; Peter Bogyi; Gabor Z Duray; Stefan H Hohnloser
Journal:  Clin Res Cardiol       Date:  2018-05-24       Impact factor: 5.460

Review 2.  His bundle pacing.

Authors:  Jason Payne; Ann C Garlitski; Jonathan Weinstock; Munther Homoud; Christopher Madias; N A Mark Estes
Journal:  J Interv Card Electrophysiol       Date:  2018-08-13       Impact factor: 1.900

3.  Multisite cardiac resynchronization therapy for traditional and non-traditional indications.

Authors:  Avishag Laish-Farkash; Sharon Bruoha; Vladimir Khalameizer; Chaim Yosefy; Yoav Michowitz; Mahmoud Suleiman; Amos Katz
Journal:  J Interv Card Electrophysiol       Date:  2018-02-13       Impact factor: 1.900

Review 4.  Does Cardiac Resynchronization Therapy Benefit Patients with Non-Left Bundle Branch Block Prolonged QRS Patterns?

Authors:  Mark N Belkin; Gaurav A Upadhyay
Journal:  Curr Cardiol Rep       Date:  2017-10-24       Impact factor: 2.931

5.  Determinants of Response to Cardiac Resynchronization Therapy.

Authors:  John D Allison; Yitschak Biton; Theofanie Mela
Journal:  J Innov Card Rhythm Manag       Date:  2022-05-15

6.  PR Prolongation predicts inadequate resynchronization with biventricular pacing in left bundle branch block.

Authors:  Brett D Atwater; Kasper Emerek; Peter L Sørensen; Steen M Hansen; Zak Loring; Claus Graff; Christoffer Polcwiartek; Joseph Kisslo; Peter Søgaard; Daniel J Friedman
Journal:  Pacing Clin Electrophysiol       Date:  2019-09-22       Impact factor: 1.976

7.  Geographical distribution of the P-R interval reference value of Chinese healthy adults.

Authors:  Fan Yang; Miao Ge; Tianyu Li; Lu Chai
Journal:  Int J Biometeorol       Date:  2019-06-10       Impact factor: 3.787

8.  Prevalence, predictors, and prognostic implications of PR interval prolongation in patients with heart failure.

Authors:  Theodora Nikolaidou; Pierpaolo Pellicori; Jufen Zhang; Syed Kazmi; Kevin M Goode; John G Cleland; Andrew L Clark
Journal:  Clin Res Cardiol       Date:  2017-09-15       Impact factor: 5.460

9.  Clinical effects of long-term cardiac contractility modulation (CCM) in subjects with heart failure caused by left ventricular systolic dysfunction.

Authors:  D Müller; A Remppis; P Schauerte; S Schmidt-Schweda; D Burkhoff; B Rousso; D Gutterman; J Senges; G Hindricks; K-H Kuck
Journal:  Clin Res Cardiol       Date:  2017-07-06       Impact factor: 5.460

10.  Atrioventricular Conduction Delay Predicts Impaired Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction.

Authors:  Jakub Stępniewski; Grzegorz Kopeć; Wojciech Magoń; Piotr Podolec
Journal:  Med Sci Monit       Date:  2017-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.